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Studies of acetylcholine degrading enzymes acetylcholines-
terase (AChE) and butyrylcholinesterase (BChE) in
Alzheimer’s disease (AD) have suggested their potential
role in the development of fibrillar amyloid-β (Aβ) plaques
(amyloid plaques). A recent genome-wide association study
analysis identified a novel association between genetic vari-
ations in the BCHE locus and amyloid burden. We studied
BChE immunoreactivity in hippocampal tissue sections
from AD and control cases, and examined its relationship
with amyloid plaques, neurofibrillary tangles (NFT), dystro-
phic neurites (DN) and neuropil threads (NT). Compared to
controls, AD cases had greater BChE immunoreactivity in
hippocampal neurons and neuropils in CA2/3, but not in
the CA1, CA4 and dentate gyrus. The majority of amyloid
plaques (> 80%, using a pan-amyloid marker X-34)
contained discrete neuritic clusters which were dual-
labeled with antibodies against BChE and phosphorylated
tau (clone AT8). There was no association between overall
regional BChE immunoreaction intensity and amyloid
plaque burden. In contrast to previous reports, BChE was
localized in only a fraction (~10%) of classic NFT (positive
for X-34). A similar proportion of BChE-immunoreactive
pyramidal cells were AT8 immunoreactive. Greater NFT
and DN loads were associated with greater BChE immuno-
reaction intensity in CA2/3, but not in CA1, CA4 and den-
tate gyrus. Our results demonstrate that in AD
hippocampus, BChE accumulates in neurons and plaque-
associated neuritic clusters, but only in a small proportion
of NFT. The association between greater neurofibrillary
pathology burden and markedly increased BChE immuno-
reactivity, observed selectively in CA2/3 region, could reflect
a novel compensatory mechanism. Since CA2/3 is generally
considered more resistant to AD pathology, BChE upregu-
lation could impact the cholinergic modulation of glutamate
neurotransmission to prevent/reduce neuronal excitotoxicity
in AD hippocampus.
Key words: alzheimer’s disease, amyloid, butyrylcholines-
terase, hippocampus, tau.
INTRODUCTION
Impaired cholinergic neurotransmission contributes to
cognitive dysfunction in Alzheimer’s disease (AD), thus
current symptomatic therapies for mild-to-moderate AD
aim to block the acetylcholine (Ach) degrading enzymes,
acetylcholinesterase (AChE) and butyrylcholinesterase
(BChE). The distribution and localization of AChE in
normal aging and AD are well described;1,2 however, less
is known about BChE, despite its role as an important
modulator of Ach metabolism.3–6 BChE inhibition is clini-
cally signiﬁcant as it provides beneﬁt to patients resistant
to AChE-speciﬁc inhibitor therapy.7 Furthermore, BChE
inhibition may have additional, disease-modifying effects
as it inﬂuences brain β-amyloid (Aβ) peptide concentration
and ameliorates Aβ-induced cognitive impairment.8 Re-
cently, an association was reported between genetic varia-
tion in the BChE gene locus and Aβ-containing amyloid
pathology burden measured using ﬂorbetapir positron
emission tomography (PET) imaging.9 These observations
warrant continued and more detailed analyses of BChE in
AD. The distribution and cellular localization of BChE in
the hippocampus have been described using histochemical
methods in tissue sections,5,10 but results from this procedure
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vary across laboratories.11 Furthermore, several studies,
using biochemical and histochemical methods, reported
increased BChE activity in AD,12,13 as well as an association
between BChE histochemical reaction and major neuro-
pathological lesions of AD, amyloid-structured aggregates
of ﬁbrillar Aβ in plaques (hereafter referred to as amyloid
plaques) and phosphorylated, ﬁbrillar tau amyloid in neu-
roﬁbrillary tangles (NFT).14–16 To extend these investiga-
tions, the current post mortem immunohistochemical
study used a BChE-speciﬁc antibody to analyze BChE
protein localization, distribution and immunoreaction in-
tensity in the hippocampus from normal and AD cases,
and to investigate its relation to amyloid structures of Aβ
plaques and neuroﬁbrillary pathology, targets of PET
radioligands currently in use or under development as im-
aging biomarkers for AD.17
METHODS
Cases
We examined 11 cases with clinical and neuropathological
diagnoses of AD and 10 age-matched controls with no
clinical history of dementia, from Choju Medical Institute,
Fukushimura Hospital and Ishizaki Hospital in Japan
(TableT1 1). Cases were free of neuropathological lesions
other than AD, except one AD case (#11) with coexisting
Lewy bodies in brain stem and amygdala bilaterally with
no involvement of the neocortex of hippocampus, and one
AD case (#15) with isolated, small infarctions bilaterally
in the thalamus. Clinical diagnosis of AD was based on
DSM-IV18 and NINCDS/ADRDA19 criteria. Neuropatho-
logical diagnosis was determined by a neuropathologist.
All AD cases were assigned a neuropathological diagnosis
of “deﬁnite” AD, while controls were “not AD” according
to CERAD criteria.20 NFT pathology was staged according
to Braak and Braak21 (Table 1). Review of medical records
revealed that one subject (case #14) had received donepezil
that was discontinued 1 year before death, but none of
the subjects in the study had received rivastigmine or
galantamine.
Tissue processing and histology procedures
At autopsy, brains were ﬁxed in 10% buffered formalin for 3
weeks. Coronal blocks of hippocampus were dissected at the
level of the lateral geniculate nucleus, embedded in parafﬁn,
sectioned at 5μm, and processed for immunohistochemistry
using previously published protocols22,23 and a rabbit poly-
clonal antibody against BChE (Aviva Systems Biology Q2, cata-
logue #ARP44208, lot #QC14544, dilution: 1:10), generated
against a synthetic immunogen corresponding to N-terminal
amino acids (SSLHVYDGKFLARVERVIVVSMNYRVG-
ALGFLALPGNPEAPGNMGLFDQQ) of butyrylcholin-
esterase with 100% homology to human BChE (http://www.
avivasysbio.com/bche-antibody-n-terminal-region-arp44208-
t100.html). Immunohistochemical signal was abolished in
preadsorption experiments (not shown) using synthetic
human BChE (Aviva, catalogue #AAP44208). Sections from
all subjects in the study were processed simultaneously. At
least three sections from each case were immunolabeled with
the BChE antibody, and additional three sections from each
Table 1 Case demographic details
Case no. Clinical diagnosis CDR Age (years) Sex Brain weight (g) PMI (hr) Braak stage CERAD stage
1 Control 0 84 M 1060 3 0 A
2 Control 0 85 F 1110 8 I A
3 Control 0 80 M 1230 2 I A
4 Control 0 81 M 1320 14 I A
5 Control 0 87 F 1080 10.5 I A
6 Control 0 78 F 1280 3.5 I A
7 Control 0 95 F 1190 12 I A
8 Control 0 77 M 1130 1 II A
9 Control 0 94 M 1115 15 II A
10 Control 0 85 M 1090 2.5 II B
11 AD 3 72 M 1160 4 IV B
12 AD 3 93 F 890 3 IV C
13 AD 3 74 M 1180 10 IV C
14 AD 3 83 F 990 3 V B
15 AD 3 95 F 970 2 V B
16 AD 3 90 F 990 7 V C
17 AD 3 94 F 1010 43 V C
18 AD 3 79 M 1130 6 V C
19 AD 3 68 M 1050 6 V C
20 AD 3 78 F 940 3 VI C
21 AD 3 69 F 750 16 VI C
CDR, Clinical dementia rating; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; PMI, post mortem interval.
KMizukami et al.2



















































































































case were processed with cresyl violet to delineate the
cytoarchitectural boundaries of the hippocampus as deﬁned
by Duvernoy.24
To assess the relation between BChE immunoreactivity
and plaque and neuroﬁbrillary amyloid pathology of AD,
BChE-immunoreacted sections were over-stained with the
pan-amyloid dye X-34, a highly ﬂuorescent derivative of
Congo red that labels β-sheet structure of Aβ ﬁbrils in
plaques as well as tau ﬁbrils in NFT, dystrophic neurites
(DN), and neuropil threads (NT), as previously de-
scribed.25,26 To examine the association between BChE
immunoreactivity and neuroﬁbrillary pathology speciﬁcally,
we performed dual immunoﬂuorescence using an antibody
against BChE (described above, dilution 1:20) and mouse
monoclonal antibody AT8 (ThermoQ3 , catalogue #MN1020,
lot #00184107, dilution 1:3,000) that interacts with epitopes
mapped to phosphorylated Ser202 and phosphorylated
Thr205. Primary antibodies were visualized using ﬂuores-
cent Alexa dyes conjugated to secondary antibodies
generated against rabbit (AlexaQ4 488 for BChE) and mouse
(Alexa 594 for AT8). Immunoﬂuorescently labeled sections
were coverslipped using 4′,6-diamino-2-phenylindole




We assessed BChE immunoreaction intensity by quantifying
immunoreaction product optical density (OD), using previ-
ously published protocols,23 in dentate gyrus (DG) granule
cells and molecular layers, CA4 cells and neuropils, and in
stratum oriens, pyramidale (pyramidal neurons and neuropil)
and radiata of CA1 and CA2/3. Images of neuropils in AD
cases were obtained using systematic random sampling and
therefore included areas with varying presentations of
BChE-immunoreactive plaques and surrounding, unaffected
neuropils. For each case, three sections were imaged and in
each subﬁeld three images were taken using an Olympus
BX53 microscope, equipped with an Olympus DP72 digital
camera and Olympus cellSens Standard image capture
software, using a UPlanSApo 10× objective (N.A.Q6 = 0.40;
Olympus, Tokyo, Japan). Illumination intensity was held
constant throughout image acquisition. Images were
assessed for grayscale intensity using public domain
image analysis software (Rasband, W.S., ImageJ, United
States National Institutes of Health, Bethesda, MD,
USA). X-34 and immunoﬂuorescence was visualized
using an Olympus BX53 microscope equipped with an
X-Cite series 120 Q ﬂuorescence illuminator and DAPI,
ﬂuorescein isothiocyanate (FITC), tetramethylrhodamine
(TRITC) and violet ﬁlters.
Neuroﬁbrillary and plaque amyloid pathology load
We calculated percent area of tissue occupied by X-34-
labeled amyloid structure in plaques and each of three types
of neuroﬁbrillary pathology (NFT, DN and NT) in the same
hippocampal regions assessed for BChE immunoreaction
intensity. Images of X-34 stained sections were processed
using the ImageJ threshold tool, and different types of X-34
positive amyloid pathology were identiﬁed as previously
described.26 Brieﬂy, amyloid plaques and NFT were distin-
guished based on their morphology (size and shape) and
localization (extracellular or intracellular). DN were identi-
ﬁed as X-34-positive dendritic swellings associated with
plaques (2–3μm diameter), while NT were X-34-positive
smaller caliber (≤1μm diameter) threads in the neuropil.
Ghost tangles were identiﬁed as extracellular skeletons of
advanced NFT.
BChE and X-34 colocalization
To assess the degree of colocalization/codistribution of
BChE immunoreactivity with X-34-labeled amyloid struc-
ture of plaques andNFT, dualX-34/BChE labeled structures
were quantiﬁed in each region of the hippocampus and
reported as percent of X-34-labeled amyloid plaques or
NFT containing BChE immunoreactivity.
BChE and AT8 colocalization
Colocalization/codistribution of BChE and AT8 immunoﬂu-
orescencewas assessed qualitatively in ﬁelds CA1, 2/3 and 4).
Statistical analyses
Individual values obtained for each case were combined to
calculate the mean and standard error (SEM) for each
group. In control and AD groups, we performed pairwise
comparisons of BChE immunoreactivity or X-34-labeled
pathology load in each examined subﬁeld, using the
Mann-Whitney U-test. Correlations of BChE immunore-
action intensity and X-34-labeled plaque and neuroﬁbril-
lary pathology load were made using Spearman’s R. All
results are expressed as mean± SEM and P< 0.05 was
considered statistically signiﬁcant.
RESULTS
Controls were cognitively normal (Clinical Dementia Rating
(CDR)=0) with Braak stages 0-II and CERAD score A
(except for Case 10, CERAD score B, and no plaques in
the hippocampus or DG), while AD cases were cognitively
impaired (CDR=3) with Braak stages IV-VI and CERAD
score B or C (Table 1). Both case groups had similar mean
age and post mortem intervals, but AD cases had lower
mean brain weight than controls (P< 0.05).
Butyrylcholinesterase in Alzheimer’s disease 3



















































































































BChE immunoreactivity in control and AD
hippocampus
In controls, BChE immunoreactivity was prominent in neu-
rons in the granular and polymorphic layers of DG, hilus
(CA4), and pyramidal layer in CA1 and CA2/3 ﬁelds, while
neuropil staining was low-to-moderate (FigsF1 1a,c andF2 2a,c).
Neuronal BChE immunoreactivity was localized to the cyto-
plasm in cell bodies and proximal dendritic segment, while
the nucleus was not labeled.We also observed BChE immu-
noreactivity in glial cells in the stratum oriens and in occa-
sional BChE immunoreactive ﬁbers traversing DG and
CA4 (not shown). In AD hippocampus, the overall pattern
of BChE immunoreactivity was similar to that observed in
controls; however, neuronal and neuropil BChE immunore-
activity were more intense (Figs 1b,d and 2b,d), particularly
in region CA2/3 (Fig. F33, both P< 0.05). In addition to neuro-
nal and neuropil labeling, AD cases had discrete clusters of
Fig. 1 Low-power photomicrographs of
butyrylcholinesterase (BChE) immunore-
activity in the dentate gyrus (DG: A,B)
and CA4 ﬁeld (C,D) from representative
Braak stage I control (A,C) and a Braak
stage VI AD case (B,D; arrows in B point
at plaque-like clusters of BChE immuno-
reactive neuritic elements in DG molecu-
lar layer). Scale bar = 50μm (A,B);
100μm (C,D).
Fig. 2 High magniﬁcation of butyrylcho-
linesterase (BChE) immunoreactive cells
and neuropil in pyramidal cell layer of
CA2/3 (A,B) and CA1 (C,D) ﬁelds from
representative Braak stage I control (A,
C) and a Braak stage VI AD (B,D) case.
Scale bar = 30μm (A,B); 50μm (C,D).
KMizukami et al.4



















































































































BChE immunoreactivity in theDGmolecular layer (Fig. 1b)
and in CA ﬁelds (Fig.F4 4a-f). Quantitative analysis of dual la-
bel X-34/BChE revealed that these BChE immunoreactive
clusters were localized to the majority (>80%) of X-34
labeled amyloid plaques. Plaque-associated BChE positive
clusters did not co-label with X-34 (Fig. 4a-c,d-f); however,
Fig. 3 Bar graph illustrating optical density
measurements of butyrylcholinesterase (BChE)
immunoreactivity in the hippocampus of Braak
stage I-II control (empty bars) and Braak stage
V-VI AD (solid bars) cases. DG, dentate gyrus;
SG, stratum granulosum; SM, stratummoleculare;
SO, stratum oriens; SP, stratum pyramidale;
SR, stratum radiatum. *P< 0.05; **P< 0.01;
***P< 0.001 (Mann–Whitney U-test).
Fig. 4 Dual-labeling of butyrylcholinesterase (BChE) immunoreactivity (A,D,G) and pan-amyloid X-34 ﬂuorescence (B,E,H) in the
hippocampus of a Braak stage VAD case. Clusters of BChE immunoreactive neuritic swellings (A, D) are localized to X-34-labeled plaques
(B,E) in the dentate gyrus molecular layer (A-C) and CA1 region (D-F). In panels A-C, the insets show at higher magniﬁcation the dashed-
outlined plaque; BChE-immunoreactive neuritic swellings do not colocalize with X-34-labeled dystrophic neurites (arrows). In panels D-F,
BChE-immunoreactive clusters are co-distributed, but do not co-localize, with X-34-labeled amyloid in plaque. Panels G-I illustrate lack of
colocalization of BChE with X-34-labeled neuroﬁbrillary tangles in CA1 (asterisks in H mark positions of BChE immunoreactive cells in
G). BChE and X-34 were pseudocolored and merged in (C, F and I), with BChE colored magenta and X-34 colored green. Scale bar = 100μm
(A-C); 20μm (D-F); 50μm (G-I).
Butyrylcholinesterase in Alzheimer’s disease 5



















































































































theywere immunoreactive for antibody cloneAT8 (Fig.F5 5a-c).
Only aminority (~10%) ofX-34-labeledNFT, primarily those
in the CA1 region, contained BChE immunoreactivity
(Fig. 4g-e). BChE and AT8 immunoreactivities did not
colocalize in pyramidal cells (Fig. 5d-f,g-i). We also observed
rare extracellular ghost tangles (large NFT lacking clearly
pyramidal cell shape and without visible DAPI-stained
nuclei), some of them resembling tangle-associated neuritic
clusters (TANC). The intensity of BChE immunoreaction
product in extracellular NFT was more prominent with a
more advanced ﬁbrillar structure revealed with X-34 (Fig.F6 6).
X-34-positive amyloid plaque and neuroﬁbrillary pathol-
ogy loads (% area occupied by plaques, NFT, NT or DN)
were quantiﬁed separately in hippocampal ﬁelds (Fig.F7 7).
Consistent with neuropathological diagnosis, measures of
X-34 ﬂuorescent pathology loads were greater in AD than
in controls (Fig. 7). There were several associations ob-
served between X-34-labeled neuroﬁbrillary pathology load
measures (from Fig. 7) and BChE immunoreaction intensity
measures (from Fig. 3). In the DG, greater X-34-labeled NT
load correlated with greater BChE immunoreaction inten-
sity in the granular cell layer (TableT2 2). In CA2/3, greater
loads of X-34 labeled NFT and DN correlated signiﬁcantly
with greater intensity of BChE immunoreaction in all layers,
and greater load of X-34-labeled NT correlated signiﬁcantly
with greater intensity of BChE immunoreaction in the
pyramidal cell layer and in stratum oriens (Table 2). There
were no statistically signiﬁcant associations between X-34-
labeled neuroﬁbrillary pathology load and BChE immuno-
reaction intensity in CA4 or CA1.
DISCUSSION
This study provides an antibody-based analysis of the distri-
bution and localization of BChE in normal human hippo-
campus, and its alteration and relation to amyloid structure
of plaques and neuroﬁbrillary pathology in AD. While our
method conﬁrmed the presence of BChE in amyloid
plaques, it also led to several novel ﬁndings, including: (i)
BChE is not closely associated with classic NFT, in contrast
to several prior reports; (ii) BChE immunohistochemistry
is a viable alternative to enzyme histochemicalmethods used
previously; and (iii) in AD hippocampus there is selective
up-regulation of BChE in the CA2/3 region, generally
considered more resistant to AD pathology.
The results of our immunohistochemical analyses of
BChE extend previous studies which used histochemical
detection of enzyme activity to examine BChE in aged
humans and AD hippocampus. For example, using enzyme
histochemistry, Darvesh and colleagues10 reported that
BChE localized to neurons and their processes in the poly-
morphic layer of the DG, as well as stratum oriens and
Fig. 5 Dual immunoﬂuorescence images showing overlapping butyrylcholinesterase (BChE) andAT8 immunoreactivity in plaque-associated
neuritic clusters (A-C), and no overlap between BChE and AT8 immunoreactivity in CA1 pyramidal cells (D-F and G-I). Scale
bar = 25 μm (A-F), 35 μm (G-I).
KMizukami et al.6



















































































































pyramidale of the CA ﬁelds, but not in the neuropils. While
our study also demonstrates the preponderance of BChE in
neuronal cells, we report that neuropils contain considerable
BChE immunoreactivity in all hippocampal ﬁelds. The latter
may be due to BChE containing glial cell processes, as
suggested by Mesulam and colleagues.5 While we observed
hippocampal BChE immunoreactive glial cell bodies in the
stratum oriens of CA1-3 and in the white matter of the
alveus, we were not able to resolve individual glial processes
in the neuropil and we did not observe BChE
immunoreactive glia in other hippocampal ﬁelds. In accord
with our observation of BChE immunoreactive glial cells
near myelinated ﬁber tracks in the hippocampus, Wright
and colleagues27 reported that glia labeled with BChE
enzyme histochemistry are abundant in deep cortical layers
and white matter, in both control and AD brains. The func-
tional signiﬁcance of BChE in glia remains to be determined.
In AD cases, X-34 positive amyloid plaques in the DG
molecular layer and CA ﬁelds contained clusters of BChE-
immunoreactive structures resembling ballooned axonal
Fig. 6 Sections of an AD hippocampus (CA1
region) processed for butyrylcholinesterase (BChE)
immunohistochemistry (A,C,E) and over-stained
with X-34 (B,D,F) demonstrate several types of
extracellular ghost NFT (eNFT; B,D,F) with vari-
able BChE immunoreactivity. BChE immunoreac-
tivity is not discernable in eNFT with ﬁne and
cohesive ﬁbrillary structure (A,B) while it is promi-
nent in eNFT with a more coarse and dispersed
ﬁbrillary structure (C-F). Asterisks mark positions
of the same eNFT in BChE and X-34 preparations.
Scale bar=15μm.
Butyrylcholinesterase in Alzheimer’s disease 7



















































































































terminals that were previously described as AChE-positive
neurites in immature plaques.28 These BChE-containing
clusters did not co-label with X-34, indicating lack of dense
amyloid β-sheet structure; however, their co-labeling with an-
tibody cloneAT8 suggests they contain an early (pre-ﬁbrillar)
type of phosphorylated tau aggregate. In support of our
current ﬁndings, a previous immunohistochemical study in
AD and nondemented control cases demonstrated that at
early stages of Aβ and thioﬂavin-S positive plaques, associ-
ated dystrophic neurites accumulating choline acetyltransfer-
ase and several neuropeptides lacked frank evidence of
neuroﬁbrillary pathology (i.e., immunoreactivity to Alz-50
or PHFQ7 antibodies29). Thus, BChE-immunoreactive clusters
in plaques could belong to degenerating cholinergic ﬁbers,
similar to those described using AChE histochemistry in
AD cerebral cortex.29 The cholinergic origin of the BChE-
immunoreactive clusters is additionally supported by reports
of similar structures detected using AChE immunohisto-
chemistry and histochemistry in aged monkey cerebral
cortex,30,31 and BChE enzyme histochemistry in the AD
brain.14,15,27,32,33 Our observation that the majority (>80%)
of X-34 labeled amyloid plaques contained BChE is in agree-
ment with previous reports.
We also observed a small proportion of diffuse, non-
neuritic X-34 plaques without BChE immunoreactive
clusters. This is in agreement with histochemical studies
showing incomplete overlap of AChE and BChE with
diffuse (thioﬂavin S negative) plaques.14 These and similar
observations led Mesulam and colleagues to propose that
plaque-associated BChEmay have a role in the hypothetical
Table 2 Correlation analyses of regional BChE immunoreaction intensity and X-34-labeled plaque, NFT, DN or NT pathology loads.
Spearman’s R (P-value, two tailed)
Regional X-34 pathology load BChE immunoreaction intensity (optical density in speciﬁc regional layers/structures)
DG or CA4 DG SG DG SM CA4 neurons CA4 neuropil
PL 0.46 (0.13) 0.29 (0.36) 0.48 (0.13) 0.55 (0.06)
NFT None present None present 0.39 (0.24) 0.37 (0.23)
DN None present None present 0.59 (0.054) 0.58 (0.046)
NT 0.76 (0.0045) 0.48 (0.12) 0.03 (0.30) 0.50 (0.10)
CA2/3 CA2/3 SO CA2/3 SP neurons CA2/3 SP neuropil CA2/3 SR
NFT 0.83 (0.0008) 0.88 (0.0002) 0.85 (0.0004) 0.77 (0.003)
DN 0.85 (0.0005) 0.76 (0.004) 0.76 (0.004) 0.71 (0.0096)
NT 0.62 (0.033) 0.69 (0.014) 0.53 (0.079) 0.31 (0.33)
CA1 CA1 SO CA1 SP neurons CA1 SP neuropil CA1 SR
PL 0.24 (0.42) 0.28 (0.36) 0.49 (0.092) 0.45 (0.12)
NFT 0.28 (.35) 0.41 (0.16) 0.53 (0.062) 0.56 (0.047)
DN 0.20 (0.50) 0.24 (0.43) 0.39 (0.19) 0.36 (0.22)
NT 0.08 (0.80) 0.23 (0.45) 0.44 (0.13) 0.43 (0.14)
BChE, butyrylcholinesterase; GDG, dentate gyrus (SG, stratum granulosum; SM, stratummoleculare); DN, dystrophic neurites; NFT, neuroﬁbrillary
tangles; NT, neuropil threads; PL, plaque load; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum. “Neuropil” refers to the neuropil sur-
rounding neurons in CA ﬁelds 1, 2/3, and 4.
Fig. 7 Bar graph illustrating plaque and neuroﬁ-
brillary pathology quantiﬁed by measuring per-
cent area occupied by X-34-labeled structures in
hippocampal ﬁelds of controls (empty bars) and
AD (solid bars). DG, dentate gyrus; NFT, neuroﬁ-
brillary tangles; DN, dystrophic neurites; NT,
neuropil threads, PL, plaque load. *P< 0.05.
KMizukami et al.8



















































































































conversion of diffuse plaques to compact plaques in AD.35
This is a particularly compelling idea given the possibility
that the enzymatic property of BChE in plaques differs from
that in normal cells and axons27 and is pathologically
signiﬁcant,35 particularly since the enzyme inﬂuences APP
processing36 and might contribute to Aβ production and
accumulation in AD. This is emphasized further by recently
reported evidence from a genome-wide association study in
theADNI cohort, that variations at theBChEgene locus are
associated with amyloid plaque load measured by
ﬂorbetapir PET.9
Despite the presence of BChE immunoreactivity in the
majority of X-34-labeled amyloid plaques, we found no
signiﬁcant correlation between amyloid plaque load
(%area) and overall regional BChEOD intensitymeasures.
This discrepancy could be explained by our observations
that in the hippocampus: )i) BChE is predominantly local-
ized to neurons and neuropils (regardless of plaque distribu-
tion); and (ii) BChE immunoreactivity in amyloid plaques is
restricted to discrete clusters, whereas the entire plaque area
occupied by β-sheet structure of amyloid (more dense in the
compact core and less dense in the diffuse halo) is labeled
with X-34. Additionally all AD cases in the present study
had an advanced stage of dementia (CDR=3) with similarly
heavy plaque burdens (CERAD=B or C).
Similar to our observation of a poor co-localization of
BChE and X-34-positive amyloid structure in dystrophic
neurites, we found that BChE immunoreactivity co-
localized with only a small proportion of X-34-positive
intracellular and extracellular NFT (eNFT), some of them
resembling TANC,37 in the AD hippocampus. These results
are in agreement with several analyses of cholinesterases in
eNFT which reported that cholinesterase labeling of eNFT
varies at various stages of eNFT dissolution,15 and that
cholinesterases are associated with Aβ-immunoreactive,
not tau, components of eNFT.16 The overall absence of
AT8 signal in BChE immunoreactive neurons, suggests that
tau protein in these cells has not yet ﬁbrilized and, accord-
ingly, is not detectable using amyloid-binding compounds
such as X-34 (pre-tangles or early tangles). Future studies
should employ a panel of antibodies against additional phos-
phorylated epitopes on tau, or different conformational
states of the protein, to examine more closely the relation-
ship between tau and BChE.
The ﬁnding that greater neuroﬁbrillary pathology load
correlated with higher BChE immunoreactivity in CA2/3,
but not in CA1, warrants further investigation. This regional
difference may reﬂect better resistance of CA2/3 neurons to
ﬁbrillary tau pathology in the AD brain. Up-regulated
BChE could result in less ACh at mossy ﬁber terminals
targeting CA2/3 pyramidal cells. Given the modulatory role
of ACh in glutamate release, this response could ﬁne-tune
glutamate neurotransmission at the mossy ﬁber synapse,
resulting in CA2/3 region-selective reduction in
excitotoxicity. In contrast, plaque-associated BChE may
have non-cholinergic functions and can be related to Aβ-
containing amyloid pathology progression, as hypothesized
by Geula and Mesulam.38
In conclusion, we found that in ADhippocampus, BChE-
accumulating pyramidal cells and plaque-associated neuritic
clusters do not contain dense amyloid structure typical of
classic NFT and dystrophic neurites in neuritic plaques.
However, in select areas the enzyme increase occurs in
parallel with the progression of regional neuroﬁbrillary
pathology and therefore it may precede the development
of amyloid aggregates or it could contribute to cells’ resis-
tance to such pathology. The functional consequences of
these observations remain to be explored and could have
important clinical implications for cholinergic (BChE
targeted) therapies in AD.
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